Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Virology

Background:

• Viral infections are linked to multiple sclerosis (MS) pathogenesis.
• Plasmacytoid dendritic cells (pDCs) play a role in MS and detect viral DNA via Toll-like receptor 9 (TLR9).
• TLR9 must be processed to become functional, and its activation promotes T-helper responses implicated in MS.

Purpose of the Study:

• To investigate the immunomodulatory effects of interferon-beta (IFN-β) on pDCs in MS patients.
• To determine if IFN-β affects TLR9 processing and subsequent pDC activation.
• To explore a potential mechanism for how IFN-β reduces MS exacerbations.

Main Methods:

• pDCs were isolated from healthy individuals and MS patients (relapsing-remitting MS and clinically isolated syndrome).
• Cytokine secretion from TLR9-activated pDCs was measured using ELISA and multianalyte profiling.
• TLR9 gene and protein expression levels were analyzed via DNA microarrays and western blot.

Main Results:

• Untreated MS patients' pDCs produced higher levels of IFN-α (a Th1 cytokine) upon TLR9 activation compared to healthy subjects.
• IFN-β-treated MS patients' pDCs showed reduced production of IFN-α, IL-6, and TNF-α.
• pDCs from IFN-β-treated patients had significantly lower levels of processed TLR9 protein, but normal full-length TLR9 protein and gene expression.

Conclusions:

• Interferon-beta (IFN-β) inhibits pDC activation by blocking Toll-like receptor 9 (TLR9) processing.
• This mechanism reduces the immune response to viral pathogens, potentially decreasing the frequency of MS relapses.
• This represents a novel immunomodulatory pathway for IFN-β in managing multiple sclerosis.